The Phosphoinositide 3-OH Kinase/AKT2 Pathway As a Critical Target for Farnesyltransferase Inhibitor-induced Apoptosis

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 1999 Dec 14

PMID 10594016

Citations 42

Authors

K Jiang

D Coppola

N C Crespo

S V Nicosia

A D Hamilton

S M Sebti

J Q Cheng

Affiliations

Soon will be listed here.

Abstract

Farnesyltransferase inhibitors (FTIs) represent a novel class of anticancer drugs that exhibit a remarkable ability to inhibit malignant transformation without toxicity to normal cells. However, the mechanism by which FTIs inhibit tumor growth is not well understood. Here, we demonstrate that FTI-277 inhibits phosphatidylinositol 3-OH kinase (PI 3-kinase)/AKT2-mediated growth factor- and adhesion-dependent survival pathways and induces apoptosis in human cancer cells that overexpress AKT2. Furthermore, overexpression of AKT2, but not oncogenic H-Ras, sensitizes NIH 3T3 cells to FTI-277, and a high serum level prevents FTI-277-induced apoptosis in H-Ras- but not AKT2-transformed NIH 3T3 cells. A constitutively active form of AKT2 rescues human cancer cells from FTI-277-induced apoptosis. FTI-277 inhibits insulin-like growth factor 1-induced PI 3-kinase and AKT2 activation and subsequent phosphorylation of the proapoptotic protein BAD. Integrin-dependent activation of AKT2 is also blocked by FTI-277. Thus, a mechanism for FTI inhibition of human tumor growth is by inducing apoptosis through inhibition of PI 3-kinase/AKT2-mediated cell survival and adhesion pathway.

Citing Articles

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.

Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Garcia-Sancho A, Advani R Blood Adv. 2024; 8(17):4581-4592.

PMID: 38991123 PMC: 11401221. DOI: 10.1182/bloodadvances.2024012806.

Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.

Theodosakis N, Langdon C, Micevic G, Krykbaeva I, Means R, Stern D Pigment Cell Melanoma Res. 2018; 32(2):292-302.

PMID: 30281931 PMC: 6590911. DOI: 10.1111/pcmr.12742.

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.

Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M Invest New Drugs. 2018; 37(2):307-314.

PMID: 30171497 PMC: 9594493. DOI: 10.1007/s10637-018-0662-1.

New tricks for human farnesyltransferase inhibitor: cancer and beyond.

Wang J, Yao X, Huang J Medchemcomm. 2018; 8(5):841-854.

PMID: 30108801 PMC: 6072492. DOI: 10.1039/c7md00030h.

mTOR-Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1.

Wang Q, Ren J Pharmacol Res. 2016; 111:357-373.

PMID: 27363949 PMC: 5026602. DOI: 10.1016/j.phrs.2016.06.024.

References

Alessi D, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P . Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996; 15(23):6541-51. PMC: 452479. View

Choquet D, Felsenfeld D, Sheetz M . Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages. Cell. 1997; 88(1):39-48. DOI: 10.1016/s0092-8674(00)81856-5. View

Palecek S, Loftus J, Ginsberg M, Lauffenburger D, Horwitz A . Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature. 1997; 385(6616):537-40. DOI: 10.1038/385537a0. View

Lebowitz P, Sakamuro D, Prendergast G . Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. 1997; 57(4):708-13. View

Gibbs J, Oliff A . The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol. 1997; 37:143-66. DOI: 10.1146/annurev.pharmtox.37.1.143. View

Rodriguez-Viciana P, Warne P, Khwaja A, Marte B, Pappin D, Das P . Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997; 89(3):457-67. DOI: 10.1016/s0092-8674(00)80226-3. View

Miquel K, Pradines A, Sun J, Qian Y, Hamilton A, Sebti S . GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res. 1997; 57(10):1846-50. View

Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne P, Downward J . Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997; 16(10):2783-93. PMC: 1169887. DOI: 10.1093/emboj/16.10.2783. View

Cheng J, Altomare D, Klein M, Lee W, Kruh G, Lissy N . Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene. 1997; 14(23):2793-801. DOI: 10.1038/sj.onc.1201121. View

10.

Chang H, Aoki M, Fruman D, Auger K, Bellacosa A, Tsichlis P . Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science. 1997; 276(5320):1848-50. DOI: 10.1126/science.276.5320.1848. View

11.

Stokoe D, Stephens L, Copeland T, Gaffney P, Reese C, Painter G . Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 1997; 277(5325):567-70. DOI: 10.1126/science.277.5325.567. View

12.

King W, Mattaliano M, Chan T, Tsichlis P, Brugge J . Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol. 1997; 17(8):4406-18. PMC: 232295. DOI: 10.1128/MCB.17.8.4406. View

13.

Cox A, Der C . Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochim Biophys Acta. 1997; 1333(1):F51-71. DOI: 10.1016/s0304-419x(97)00011-5. View

14.

Van Aelst L, DSouza-Schorey C . Rho GTPases and signaling networks. Genes Dev. 1997; 11(18):2295-322. DOI: 10.1101/gad.11.18.2295. View

15.

Short S, Talbott G, Juliano R . Integrin-mediated signaling events in human endothelial cells. Mol Biol Cell. 1998; 9(8):1969-80. PMC: 25448. DOI: 10.1091/mbc.9.8.1969. View

16.

Mitsuuchi Y, Johnson S, Moonblatt S, Testa J . Translocation and activation of AKT2 in response to stimulation by insulin. J Cell Biochem. 1998; 70(4):433-41. View

17.

He T, Sparks A, Rago C, Hermeking H, Zawel L, DA COSTA L . Identification of c-MYC as a target of the APC pathway. Science. 1998; 281(5382):1509-12. DOI: 10.1126/science.281.5382.1509. View

18.

Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S . Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A. 1998; 95(19):11211-6. PMC: 21621. DOI: 10.1073/pnas.95.19.11211. View

19.

Klippel A, Escobedo M, Wachowicz M, Apell G, Brown T, Giedlin M . Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol. 1998; 18(10):5699-711. PMC: 109156. DOI: 10.1128/MCB.18.10.5699. View

20.

Le Good J, ZIEGLER W, Parekh D, Alessi D, Cohen P, Parker P . Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science. 1998; 281(5385):2042-5. DOI: 10.1126/science.281.5385.2042. View